Call us for quotes at (610) 458-1112 or 
Email us at primbiobiz@primbioresearch.com
PrimBio
  • Home
  • Company
    • About Us
    • Our Team
    • Publications
    • Careers
  • Technology
    • Illumina NextSeq 2000
    • Ion GeneStudio™ S5 Prime System
    • QuantStudio™ 12K PCR System
  • Research Services
    • RNA-seq
    • Exome Sequencing
    • Gene Panels
    • 16S Metagenomic Sequencing
    • Real-time qPCR
  • Clinical Tests
    • Cancer Hotspot Panel
    • Colorectal Cancer Panel
    • Breast Cancer Therapy Panel
    • COVID-19 RT-PCR TEST
    • UTI QPCR TEST
    • COVID/FLU/RSV RT-PCR TEST
  • Get a Quote
  • Home
  • Company
    • About Us
    • Our Team
    • Publications
    • Careers
  • Technology
    • Illumina NextSeq 2000
    • Ion GeneStudio™ S5 Prime System
    • QuantStudio™ 12K PCR System
  • Research Services
    • RNA-seq
    • Exome Sequencing
    • Gene Panels
    • 16S Metagenomic Sequencing
    • Real-time qPCR
  • Clinical Tests
    • Cancer Hotspot Panel
    • Colorectal Cancer Panel
    • Breast Cancer Therapy Panel
    • COVID-19 RT-PCR TEST
    • UTI QPCR TEST
    • COVID/FLU/RSV RT-PCR TEST
  • Get a Quote

Primbio MSi Cancer Panel

The PrimBio Microsatellite Instability (MSI) panel uses Ion Ampliseq technology to amplify 76 loci that are associated with MSI.  These markers include the 5 original markers laid out by the Bethesda Panel for Colorectal Cancer and 71 other regions that are highly susceptible to insertions or deletions of nucleotide repeats.  Due to the large number of microsatellite regions analyzed, this method of NGS analysis of MSI has been developed without matched normal tissue. Instead, the comparison of these microsatellite sequences to a reference human genome was able to provide the level of sensitivity achieved by the standard method. Thus, this MSI NGS panel makes it feasible to determine MSI status in patients lacking normal tissue.
​
Molecular Diagnostic 
​Requisition Form
Sample Submission
​Guidelines

© COPYRIGHT 2016. ALL RIGHTS RESERVED.